IHH Healthcare's damages against Daiichi could reach $1.25 billion, expert report says (Feb 6)
IHH Healthcare said on Thursday its unit submitted an expert report to a Tokyo court which states damages sought from Japan's ...
Channel NewsAsia Singapore7d
IHH Healthcare's unit seeks up to $1.25 billion from Japan's Daiichi over Fortis deal
Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) ...
Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight
DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...
Competitive Intelligence in Breast Cancer: Tracking the Evolving HR+ HER2-ve Breast Cancer Landscape
A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top ...
Nasdaq17d
FDA Approves AstraZeneca And Daiichi Sankyo's ENHERTU For HER2-Low/Ultralow Breast Cancer
(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...
Business Insider22d
Daiichi Sankyo’s Growth Prospects Bolstered by FDA Approval of Dato-DXd and Upcoming Catalysts
Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price target of Yen7,600.00. Stephen Barker has given his Buy ...
Sports Illustrated24d
Super Bowl Logos Through the Years: A Look at How They’ve Evolved
Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...
BioSpace24d
After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period
However, the asset faced a series of setbacks in 2024. The FDA on Friday approved AstraZeneca and Daiichi Sankyo’s Dato-DXd, to be known as Datroway, for patients with certain advanced breast ...
BioSpace24d
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway will cost nearly $4,900 per vial, Reuters reported. The treatment will hit U.S. shelves in approximately two weeks, according to Daiichi Sankyo’s announcement of the approval. In a note to ...
Daily24d
AstraZeneca-Daiichi Sankyo Datroway gets USFDA nod for previously treated Metastatic HR Positive, HER2 Negative Breast Cancer
Tokyo: D aichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) ...
MarketWatch25d
Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...